Fate Therapeutics Inc (FATE)
NASDAQ:FATE
Want to see FATE full AI Analyst Report?
FATE Stock Chart & Stats
$1.39
-$0.10(-5.71%)
At close: 4:00 PM EST
$1.39
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.91 - $2.88
Previous CloseN/A
Volume630.90K
Average Volume (3M)4.28M
Market Cap
$257.60M
Enterprise Value$368.24M
Total Cash (Recent Filing)$174.82M
Total Debt (Recent Filing)$76.78M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Aug 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding116,559,190
10 Day Avg. Volume5,751,129
30 Day Avg. Volume4,281,633
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue58.30
Enterprise Value/Gross Profit108.37
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$4.78Price Target Upside244.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$5.30M
Bulls Say, Bears Say
Bulls Say
Scalable IPSC PlatformFate’s iPSC-based off-the-shelf model enables multi-patient manufacturing runs and outpatient-enabled administration. Structurally this can lower per-patient costs, simplify supply chain versus autologous therapies, and support scalable commercial manufacturing and durable margin improvement.
Registrational FT819 ProgramA planned Phase 2 registrational trial for FT819 shifts the program toward a clear regulatory pathway. Registrational intent materially de-risks development compared with exploratory studies and, if successful, shortens time to potential approval and sustainable revenue generation.
Manageable LeverageReported debt-to-equity near 0.43 indicates leverage remains moderate for a clinical-stage biotech. This balance-sheet positioning provides some financial flexibility to fund ongoing trials and operations over the medium term without immediate distress-level leverage constraints.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow of roughly -$100M TTM requires frequent external financing. This structural cash burn elevates dilution risk, constrains strategic optionality for program funding, and increases pressure on management to secure capital while advancing long-duration trials.
Minimal Commercial RevenueVery low and declining revenue with negative gross profit indicates the company lacks self-sustaining commercial operations. Reliance on clinical progress and financing rather than product cash flow raises sustainability risk until a product reaches approval and market uptake.
Shrinking Equity BaseEquity declining sharply over several years reflects accumulated losses and capital erosion. A reduced equity cushion lowers loss-absorbing capacity, heightens refinancing vulnerability, and increases the company’s sensitivity to adverse trial outcomes or funding delays over the medium term.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was $0.91 and its highest was $2.88 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is $257.60M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Aug 05, 2026 which is in 59 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Fate Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.02.
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate is -0.27.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 116,559,190 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Fate Therapeutics Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -5.111%.
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.78 (244.12% Upside)
$4.78 (244.12% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 188.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.76%
12-Months-Change
Fundamentals
Return on Equity
-58.89%
Trailing 12-Months
Asset Growth
-28.53%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$4.78
▲(244.12% Upside)
Technical Analysis
Ownership Overview
12.81% Insiders
12.84% Mutual Funds
19.21% Other Institutional Investors
46.44% Public Companies and
Individual Investors